Source comparison
Melanotan 1 vs 2: Fitzpatrick Skin Type Considerations
Fitzpatrick skin type is an important variable when comparing melanotan 1 vs 2 for tanning research. The Fitzpatrick scale classifies skin into six phototypes based on melanin content and UV response: Type I (always burns, never tans) through Type VI (deeply p
This comparison does not assign a generated winner or score.
- Fitzpatrick skin type is an important variable when comparing melanotan 1 vs 2 for tanning research. The Fitzpatrick scale classifies skin into six phototypes based on melanin content and UV response: Type I (always burns, never tans) through Type VI (deeply pigmented, never burns). Research on afamelanotide (melanotan 1) initially focused on Fitzpatrick Types I and II subjects with erythropoietic protoporphyria — individuals whose photosensitivity made sun exposure clinically dangerous. In these populations, melanotan 1 produced protective eumelanin increases that enabled meaningful sun exposure without phototoxic reactions.
- For melanotan 2, anecdotal and informal research data suggests similar responses across Fitzpatrick types, with the non-tanning effects (nausea, libido enhancement) appearing consistently across skin types but tanning magnitude varying based on baseline melanocyte activity. Researchers with darker baseline skin (Fitzpatrick Types IV-VI) may observe less dramatic visual tanning changes with either compound due to higher baseline melanin levels — though the cellular mechanisms of MC1R stimulation remain consistent regardless of skin type. Understanding Fitzpatrick classification helps researchers frame their melanotan 1 vs 2 data in the appropriate physiological context.
- When designing a melanotan 1 vs 2 research protocol that accounts for skin type, researchers should note that individuals with higher baseline melanin have more pre-existing eumelanin in follicular units, which means the incremental change from peptide administration may be more subtle visually while still representing a measurable increase in melanin synthesis at the cellular level. Published afamelanotide research consistently stratifies results by Fitzpatrick type, and the 2015 NEJM trial on afamelanotide enrolled exclusively Type I-III subjects, making its findings most directly applicable to fair-skinned research contexts.